Sequencing of Liposomal Daunorubicin/Cytarabine Versus Hypomethylating Agents Plus Venetoclax for Secondary Acute Myeloid Leukemia

Author(s)Alan Flores, PharmD, Jose Tinajero, PharmD, BCOP, Dat Ngo, PharmD

Fact checked by: Luke Halpern, Associate Editor

This abstract will be presented at the Oncology Pharmacists Connect (OPC) meeting in Austin, Texas, from June 19 to 20, 2025.

Alan Flores, PharmD, Jose Tinajero, PharmD, BCOP, and Dat Ngo, PharmD, BCOP, are set to present their abstract "Sequencing of Liposomal Daunorubicin/Cytarabine (Vyxeos) vs Hypomethylating Agents Plus Venetoclax for Secondary Acute Myeloid Leukemia" at the 2025 Oncology Pharmacists Connect (OPC) meeting in Austin, Texas, from June 19 to 20. The abstract explores treatment sequencing in patients with secondary acute myeloid leukemia (sAML) who received both liposomal daunorubicin/cytarabine and hypomethylating agents with venetoclax during their care.